GoDubai
  
  
  
  
Citylife > Press Release
  Home Contact us Add to Favourites
Most Recent Postings
More Press Releses
Featured Sections

Event Finder
A daily roundup of exhibitions, promotions and other events in Dubai and the rest of the Emirates.
Submit an Event
Latest Dubai Press Releases >>

 
  Share
  • The pharmaceutical leader conducted an industry-first head-to-head study of two biologic therapies commonly used to treat the illness: vedolizumab and adalimumab
  • Vedolizumab was found to be superior in achieving clinical remission and mucosal healing at week 52
  • Study focused on patients with moderately to severely active ulcerative colitis  
Dubai, UAE, March 11, 2019:   Global biopharmaceutical company Takeda today announced the results of its pioneering VARSITY study into the effectiveness of two common therapies used to treat Ulcerative Colitis. Shared at the 14th Congress of the European Crohn's and Colitis Organization (ECCO) in Copenhagen Denmark, the findings showed that the use of vedolizumab – a gut-selective biologic treatment, was more effective overall at tackling the illness when compared to adalimumab– a common anti-tumor therapy.
 
Specifically, the study found that by week 52 of treatment among patients with moderate to severely active ulcerative colitis, 31.3 percent of those receiving vedolizumab intravenously experienced clinical remission*, compared to 22.5 percent of patients receiving adalimumab via injection at week 52. In addition, 39.7 percent of patients treated with vedolizumab recorded mucosal healing** - a slowing of the disease's progression, compared to 27.7 percent of those receiving adalimumab.
 
A non-statistically significant difference in favor of adalimumab was seen among patients who stopped taking oral corticosteroids - steroid hormones that are usually produced in the adrenal gland and were in clinical remission*** at week 52. Meanwhile, although the study was not conducted to compare the safety of the two treatments, patients treated with vedolizumab had a lower rate (62.7 percent) of adverse effects over 52 weeks compared to patients receiving adalimumab treatment (69.2 percent). Those treated with vedolizumab recorded a lower rate of infection (33.5 percent) compared to patients treated with adalimumab (43.5 percent). The rate of serious adverse events was also lower in vedolizumab-treated patients than adalimumab (11.0% vs. 13.7% respectively).
 
“The VARSITY study addresses critical questions concerning the selection of biologic therapy in ulcerative colitis. The goal of treatment of this disease is to achieve clinical remission and mucosal healing, and these results clearly highlight the benefits seen with vedolizumab versus adalimumab towards these important outcomes.” said Dr. Bruce E. Sands, primary investigator of the VARSITY study and Chief of both the Dr. Henry D. Janowitz Division of
Gastroenterology at Mount Sinai Hospital, and the Icahn School of Medicine at Mount Sinai in New York.
 
Jeff Bornstein, M.D., Executive Medical Director, Takeda added, “The study gives physicians invaluable knowledge towards treatment decisions when starting biologic therapy. This is also the first time we have seen a direct comparison between two medicines with distinct modes of action in ulcerative colitis. This is an exciting time in the landscape of ulcerative colitis treatment, as head-to-head clinical data has not previously been available to guide treatment decisions around biologic therapies.”
 
The VARSITY study comprised a random selection of 769 patients, all of whom had shown an inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or one TNFα-antagonist other than adalimumab before being enrolled. 
 
Patients were randomly placed into one of two treatment groups - vedolizumab IV and placebo SC or adalimumab SC and placebo IV. Patients in the vedolizumab group were administered 300 mg of vedolizumab IV at weeks 0, 2, 6 and every 8 weeks after until week 46, along with placebo SC at week 0 and every 2 weeks until week 50. The adalimumab group were administered 160 mg of adalimumab SC at week 0, 80 mg at week 2 and 40 mg every 2 weeks until week 50, along with placebo IV at weeks 0, 2, 6 and every 8 weeks thereafter until week 46. Dose escalation was not permitted in either treatment arm during the study.1, 



Posted by : GoDubai Editorial Team
Viewed 7282 times
Posted on : Monday, March 11, 2019  
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of GoDubai.com.
Previous Story : A New Manufacturing Approach to Optical Transceivers
Next Story : RAK Hospital wins MRM business award for the 2nd time
Email this article Print this article

Share this article with your friends and followers
NewsVine

Comments

Back to Top  
Most Viewed Press Release posted in the last 7 days
Lockdown Showdown: Jaguar I-pace Etrophy Series to Get Back on Track in Berlin i...
Three Eggs get Yemeni National a Guinness World Records Title
Omega's Antimagnetic Tourbillon Is a Watchmaking Breakthrough
Lamborghini SCV12: Squadra Corse Hypercar Ready to Hit the Track
The new BMW M5 and BMW M5 Competition
Toric Tourbillon Slate
GROHE Smart Control Review
Twitter tests Tweeting with Voice
Saxo Bank Launches Loyalty Program for MENA Region Clients
Hyundai Motor and Sony Pictures Entertainment Announce Unique and Pioneering Mul...
American Aesthetic Medical Center Has Something in Store for the Esthetical Figu...
WTTC Launches Safe Travels Protocols for Attractions, Car Hire and Short-Term Rental
NUDESTIX Launches - Nudies Blush, Bronze, and Glow Shade Extension
Volvo Cars Chengdu Car Plant Powered by 100 Per Cent Renewable Electricity
Range Rover Marks 50 Years of All-terrain Innovation and Luxury With Exclusive N...
Under-12 and Over-60 Can Now Take Part in Sports Activities: Dubai Sports Council
Dabur Ensures Safety with Hand Sanitizers and Personal Protection Kits as UAE Es...
Let's Brigthen Up! The Face Shop's Ultimate Summer Skincare Range From Belif is Here!
Handy Helper for Content Creators: The Compact A6100 Mirrorless Camera from Sony...
Pre-orders for Samsung's Galaxy S20+ 5G and Galaxy Buds+ BTS Edition now open in...
Experts Highlight need for Young Talent to Develop Skills for a Post-Covid-19 World
Dabur Launches Pure Organic Coconut Oil: Natural Protection for Hair, Skin, and ...
GEMS Wellington Academy – Al Khail Improves Rating to 'Very Good' in KHDA DSIB 2...
Etihad Airways to Recommence Flights to Athens
Dubai Sees Pronounced Uptick in Demand for Retail Units
Book Building of Amlak International's IPO of 30% of Shares
Sanctuary for the Senses: All-New Lincoln Corsair Arrives with Whisper-Quiet, Co...
Essence Spring/Summer 2020 Collection
Registration Opens for Training On the Camel Trek and Camel Marathon for Expats
Covid-19 Leads UAE Businesses to Adopt Upgraded Green Building Solutions
Dubai Sports Council Discuss Upcoming Sports Events With Federations and Organisers
Dubai Sports Council to Celebrate Dubai's COVID-19 Heroes Through Commemorative ...
Turkish Airlines Was the Busiest Operator in the Eurocontrol Area After Restarti...
Celebrate Father's Day With Parmigiani Fleurier Tondagraph Slate'
INFINITI of Arabian Automobiles presents Dubai Islamic Bank customers Super Sale...
Crude Oil Headwinds on Virus and Technicals
Customers can Benefit from Increasing Gold Rate by just Paying 10% Advance at Ma...
Canadian University Dubai Receives Prestigious Certification in Education for Pu...
Report Reveals the Six Fintech Innovations That Will Boost the ‘Financial Health...
Serco Middle East Appoints New Managing Director for Dubai Metro and Dubai Tram
Big Bang Integral King Gold
Pan Emirates Unveils Exclusive New Collection
Digital Vision Technology Signals On-Track Success for Panasonic Jaguar Racing
Schneider Electric Extends Strategic Partnerships with AVEVA, Lenovo and Stratus...
Celebrate World Music Day with HONOR Magic Earbuds
The 11th Edition of the Arab Fashion Week to Launch Virtually Today, from June 2...
New Bentayga to Launch Beyond100
Cairo Amman Bank Adopts the Latest Technology to Enhance Performance and Securit...
Celebrate Summer Safely with the New, Shopping Normal at BurJuman
Registration open for Dubai Watersports Summer Week